RT Journal Article
T1 Cannabinoids and Gliomas
A1 Velasco Díez, Guillermo
A1 Carracedo, Arkaitz
A1 Blázquez Ortiz, Cristina
A1 Lorente Pérez, María Del Mar
A1 Aguado Sánchez, Tania
A1 Haro, Amador
A1 Sánchez García, María Cristina
A1 Galve Roperh, Ismael
A1 Guzmán Pastor, Manuel
AB Cannabinoids, the active components of Cannabis sativa L., act in the body by mimicking endogenous substances—the endocannabinoids—that activate specific cell surface receptors. Cannabinoids exert various palliative effects in cancer patients. In addition, cannabinoids inhibit the growth of different types of tumor cells, including glioma cells, in laboratory animals. They do so by modulating key cell signaling pathways, mostly the endoplasmic reticulum stress response, thereby inducing antitumoral actions such as the apoptotic death of tumor cells and the inhibition of tumor angiogenesis. Of interest, cannabinoids seem to be selective antitumoral compounds, as they kill glioma cells, but not their non-transformed astroglial counterparts. On the basis of these preclinical findings, a pilot clinical study of Δ9-tetrahydrocannabinol (THC) in patients with recurrent glioblastoma multiforme has been recently run. The good safety profile of THC, together with its possible growth-inhibiting action on tumor cells, justifies the setting up of future trials aimed at evaluating the potential antitumoral activity of cannabinoids.
PB Springer
SN 0893-7648
YR 2007
FD 2007
LK https://hdl.handle.net/20.500.14352/91631
UL https://hdl.handle.net/20.500.14352/91631
LA eng
NO Velasco, G., Carracedo, A., Blázquez, C. et al. Cannabinoids and Gliomas. Mol Neurobiol 36, 60–67 (2007). https://doi.org/10.1007/s12035-007-0002-5
NO Ministerio de Educación y Ciencia (España)
NO Comunidad de Madrid
NO Fundación Mutua Madrileña 
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 4 abr 2025